Conmed (CNMD) Tops Q2 EPS by 4c, provides outlook

Conmed (NYSE: CNMD) reported Q2 EPS of $0.83, $0.04 better than the analyst estimate of $0.79. Revenue for the quarter came in at $317.7 million versus the consensus estimate of $306.06 million.

2023 Outlook

Based on the second quarter results, the Company is raising its revenue guidance for the full year 2023 and now expects revenue between $1.230 billion and $1.260 billion, compared to its prior guidance of between $1.205 billion and $1.250 billion.

The Company now expects full-year 2023 adjusted diluted net earnings per share(2) in the range of $3.40 to $3.55, compared to its prior range of $3.30 to $3.50.

The expected impact of foreign currency exchange rates is unchanged from the Company’s prior guidance.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Carnival shares drop despite earnings beat on weak guidance
• BofA lists top 5 themes driving next $1tn in incremental semi sales